Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Harrow Launches VIGAMOX in the U.S.
Details : VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) is a fluoroquinolone antibiotic eye drop approved for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Product Name : Vigamox
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2023
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Ophthalmology Associates, St Louis | Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2011
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Ophthalmology Associates, St Louis | Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2010
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
